Renal & Urinary

Benign prostatic hyperplasia: medical and surgical management

Clinical Overview and When to Suspect BPH

— Histologic BPH present in ~50% of men by age 60 and ~90% by age 85

— Symptomatic LUTS affects ~25% of men >50; prevalence rises with age, obesity, metabolic syndrome

— Strong association with type 2 diabetes, dyslipidemia, low physical activity

— Dihydrotestosterone (DHT)-driven glandular growth via 5α-reductase type 2 in stromal cells

— Dynamic component: α1A-adrenergic tone in prostatic smooth muscle and bladder neck

— Static component: physical mass effect of enlarged transition zone

— Storage (irritative) symptoms: urgency, frequency, nocturia, urge incontinence

— Voiding (obstructive) symptoms: hesitancy, weak stream, intermittency, straining, incomplete emptying, terminal dribbling

— Often progressive over months to years; usually no hematuria, no flank pain, no constitutional symptoms

— Gross hematuria → bladder cancer workup (cystoscopy + upper tract imaging)

— Fevers, perineal pain → prostatitis

— Weight loss, bone pain, hard nodular prostate → prostate cancer

— Neurologic deficits, saddle anesthesia → neurogenic bladder/cauda equina

— Young patient (<45) with LUTS → reconsider diagnosis (urethral stricture, bladder neck dysfunction)

Board pearl: BPH size does not correlate with symptoms. A small prostate with high α-adrenergic tone can cause severe LUTS; a huge gland may be asymptomatic. Always quantify symptom burden (AUA-SI/IPSS) and bother score — not just gland volume — to drive management.

Definition: Benign prostatic hyperplasia is a histologic diagnosis of stromal and glandular hyperplasia in the transition zone of the prostate, clinically manifesting as lower urinary tract symptoms (LUTS) and/or bladder outlet obstruction (BOO).

Epidemiology:

Pathophysiology highlights:

When to suspect BPH (Step 3 outpatient framing): middle-aged or older man presenting with:

Red flags that argue AGAINST simple BPH:

Presentation Patterns and Key History

— 7 questions scored 0–5 each (total 0–35)

— Mild 0–7, Moderate 8–19, Severe 20–35

— Add separate bother/QoL question (0–6) — drives whether to treat

— Frequency (>8 voids/day)

— Urgency

— Nocturia (≥2 episodes is clinically significant)

— Weak stream

— Intermittency

— Straining

— Emptying incomplete (post-void dribble, sense of residual)

— Duration, progression, prior episodes of acute urinary retention (AUR)

— Medication review — critical Step 3 task:

— Anticholinergics (TCAs, oxybutynin, diphenhydramine, antipsychotics) worsen voiding

— Sympathomimetics (pseudoephedrine, OTC cold meds) tighten bladder neck → can precipitate AUR

— Diuretics → polyuria mimicking BPH frequency

— Opioids → urinary retention

— Testosterone supplementation can enlarge prostate

— Fluid/caffeine/alcohol/evening fluid intake — nocturia driver

— Sexual function baseline (erectile function, ejaculation) — affects drug choice

— Hematuria, dysuria, fevers, stones, prior catheterization, pelvic surgery/radiation

— Neurologic history: stroke, Parkinson, MS, diabetic neuropathy, spinal cord injury

— Sleep disruption from nocturia → falls in elderly

— Driving/work limitations from frequency

— Sexual dysfunction often coexists

Step 3 management: Before labeling LUTS as BPH and starting a drug, review the med list and modify lifestyle (limit evening fluids, caffeine, alcohol; timed voiding; treat constipation). Many "BPH" presentations improve dramatically once an OTC antihistamine or pseudoephedrine is stopped — cheaper, safer, and the expected first move on a Step 3 vignette emphasizing stewardship.

Symptom framework — use the AUA Symptom Index (AUA-SI) / IPSS:

Storage ("irritative") symptoms — FUN:

Voiding ("obstructive") symptoms — WISE:

Targeted history must capture:

Functional/QoL assessment:

Physical Exam Findings and Functional Assessment

— Palpate the suprapubic region — distended bladder suggests chronic retention; dullness to percussion above the pubic symphysis

— Costovertebral angle tenderness → suggests upper tract involvement (hydronephrosis, pyelonephritis)

— Lower extremity edema — could indicate post-renal azotemia

— Benign BPH prostate: symmetrically enlarged, smooth, rubbery, non-tender, preserved median sulcus

— Concerning findings:

— Hard, nodular, asymmetric → prostate cancer — needs urology referral and PSA

— Boggy, exquisitely tender, warm → acute bacterial prostatitis — do NOT vigorously massage (bacteremia risk)

— Fluctuant → prostatic abscess

— Limitation: DRE assesses only the posterior peripheral zone; transition-zone enlargement (the BPH zone) may not be appreciated

— Lower extremity strength, reflexes, sensation (especially perineal/saddle)

— Bulbocavernosus reflex, anal tone — absent in cauda equina, spinal cord pathology

— Gait, cognition (Parkinson, NPH triad: gait/urinary/cognitive)

— Meatal stenosis, phimosis, palpable urethral mass (stricture, tumor)

— Testicular exam for completeness

— Timed get-up-and-go, fall risk — surgical candidacy

— Cognitive screening if considering anticholinergics

— Functional incontinence vs true BPH (mobility-limited patient who can't reach bathroom)

Key distinction: A tender, boggy prostate in a febrile man is acute prostatitis, not BPH — start fluoroquinolone or TMP-SMX, obtain urine culture, and avoid prostate massage, which can seed bacteremia. Treating this as BPH and starting an α-blocker would be a classic Step 3 distractor.

General/abdominal exam:

Digital rectal exam (DRE) — required component:

Focused neurologic exam (rule out neurogenic bladder):

Genital exam:

Functional and frailty assessment (Step 3 outpatient flavor):

Diagnostic Workup — Initial Labs and Studies

— Urinalysis — every patient

— Hematuria → cystoscopy + upper tract imaging (CT urogram or renal US)

— Pyuria/nitrites → treat UTI first, then reassess LUTS

— Glucosuria → check for diabetes-driven polyuria

— Serum creatinine — not routinely required by AUA, but obtain if suspicion of retention/obstruction or if planning contrast imaging; check eGFR before drug dosing

— PSA — shared decision-making

— Indicated if life expectancy >10 years AND result would change management

— Also useful as a surrogate for prostate volume (PSA >1.5 ng/mL predicts gland >30 g → better 5-ARI response)

— Counsel that BPH itself raises PSA (~0.3 ng/mL per gram of tissue); DRE, ejaculation, prostatitis, catheterization also elevate it

— IPSS/AUA-SI at baseline and follow-up — the numerical anchor for therapy decisions

— Voiding diary (3 days) — especially when nocturia dominates (distinguish polyuria, nocturnal polyuria, low bladder capacity)

— Normal <50 mL; >200 mL suggests significant retention

— Influences medication choice (avoid anticholinergics if elevated PVR) and surgical urgency

— Qmax <10 mL/s strongly suggests BOO; >15 mL/s argues against

— Not routine for uncomplicated BPH

— Renal US if elevated creatinine, recurrent UTI, hematuria, stones, or palpable bladder

— Transrectal US (TRUS) to measure prostate volume before surgery

Board pearl: Microscopic hematuria + LUTS in a man >35 with smoking history = cystoscopy, not "start tamsulosin." Missing bladder cancer behind a BPH label is a recurring Step 3 trap. AUA recommends cystoscopy and CT urogram for any unexplained microhematuria in adults at intermediate–high risk.

Required baseline workup for new LUTS (AUA guideline):

Symptom quantification:

Post-void residual (PVR) — bedside bladder scan:

Uroflowmetry (often urology office):

Imaging:

Diagnostic Workup — Advanced and Confirmatory Studies

— Refractory symptoms despite optimized medical therapy

— Recurrent UTI, gross hematuria, bladder stones

— Renal insufficiency attributed to obstruction

— Recurrent or refractory urinary retention

— Suspected neurogenic bladder, stricture, or prior pelvic surgery/radiation

— Considering surgical intervention

— Pressure-flow study is the gold standard to distinguish BOO from detrusor underactivity

— Critical when symptoms don't match exam (e.g., severe LUTS but small prostate, or large prostate but minimal symptoms)

— Mandatory before surgery in patients with: prior surgical failure, neurologic disease, age <50 or >80, PVR >300 mL, or suspected detrusor failure

— Indications: hematuria, suspected stricture, prior urologic surgery, planning surgical approach (size/shape of median lobe matters)

— Visualizes urethra, prostatic lobes, bladder mucosa, trabeculation, diverticula, stones

— Measures prostate volume and configuration (presence of intravesical median lobe)

— Guides surgical selection:

— <30 g → TUIP or TURP

— 30–80 g → TURP, laser enucleation, water vapor (Rezūm), PUL (UroLift)

— >80 g → simple prostatectomy (open/robotic) or HoLEP

— Not for BPH per se; ordered when PSA elevation raises cancer concern (PI-RADS scoring) or to map gland anatomy before complex surgery

— Only for cancer concern (abnormal DRE, rising/elevated PSA after risk stratification, MRI lesion PI-RADS 3–5)

Step 3 management: Pressure-flow urodynamics are the definitive arbiter when you must decide whether a man's LUTS are obstructive (will benefit from TURP) versus from an underactive detrusor (won't, and may worsen incontinence). Send the ambiguous patient for UDS before greenlighting surgery.

When to refer to urology for advanced testing:

Urodynamic studies (UDS):

Cystoscopy:

Transrectal ultrasound (TRUS):

MRI prostate:

Prostate biopsy:

Risk Stratification and First-Line Management Logic

— Mild (IPSS 0–7) or no bother: watchful waiting + lifestyle

— Moderate (8–19) with bother: medical therapy

— Severe (20–35) or complications: medical therapy ± early surgical referral

— Prostate volume >30–40 g

— PSA >1.5 ng/mL

— Age >70

— PVR >100 mL, Qmax <10 mL/s

— Prior episode of AUR

— Refractory or recurrent urinary retention

— Recurrent UTIs from incomplete emptying

— Recurrent gross hematuria from BPH (after ruling out other causes)

— Bladder stones secondary to BOO

— Renal insufficiency from obstruction

— Large bladder diverticula

— Reduce evening fluids, caffeine, alcohol

— Avoid bladder irritants (spicy food, artificial sweeteners in sensitive patients)

— Timed/double voiding

— Treat constipation (it worsens LUTS)

— Weight loss, exercise (metabolic syndrome worsens BPH)

— Bladder training, pelvic floor PT for storage-predominant symptoms

— Review and stop offending meds (anticholinergics, sympathomimetics)

— Discuss efficacy timelines (α-blockers days; 5-ARIs 3–6 months)

— Sexual side effects of each drug class

— Cost and adherence

— Surgical alternatives if medication burden is unacceptable

Board pearl: A man with large gland (PSA >1.5, volume >40 g) and moderate symptoms should get combination α-blocker + 5-ARI — the MTOPS and CombAT trials showed combination reduces clinical progression and AUR more than monotherapy. Small gland? α-blocker alone suffices.

Step 1 — Categorize by IPSS + bother:

Step 2 — Identify "progression risk" features that push toward 5α-reductase inhibitors (5-ARIs) and earlier surgery:

Step 3 — Identify absolute indications for surgery (won't resolve with meds):

Lifestyle/behavioral measures — always first-line, always continued:

Shared decision-making framework:

Pharmacotherapy — First-Line Drug Regimens

— Mechanism: relax prostatic and bladder neck smooth muscle (α1A)

— Onset: days to weeks — fastest symptom relief

— Do NOT shrink the prostate or prevent progression/AUR

— Agents:

— Uroselective (α1A): tamsulosin 0.4 mg, silodosin 8 mg, alfuzosin 10 mg — fewer cardiovascular effects

— Nonselective: terazosin, doxazosin — also lower BP, useful if comorbid HTN, but require titration

— Adverse effects: orthostatic hypotension, dizziness, retrograde/anejaculation (silodosin > tamsulosin), nasal congestion, syncope

— Floppy iris syndrome (IFIS): stop tamsulosin and notify ophthalmologist BEFORE cataract surgery — but discontinuation does not fully reverse risk

— Agents: finasteride 5 mg, dutasteride 0.5 mg

— Mechanism: block conversion of testosterone → DHT, shrinking glandular tissue by ~20–25%

— Onset: 3–6 months for symptom improvement

— Indicated when prostate >30–40 g or PSA >1.5 ng/mL

— Reduce risk of AUR and need for surgery (MTOPS, CombAT)

— Lowers PSA by ~50% after 6 months — double the measured PSA when screening for cancer

— Adverse effects: decreased libido, ED, ejaculatory dysfunction, gynecomastia, depression

— Pregnancy category X — women of childbearing potential should not handle crushed tabs

Step 3 management: Start tamsulosin for moderate LUTS, add finasteride if prostate >40 g/PSA >1.5, swap to tadalafil daily when ED coexists, and add an antimuscarinic or mirabegron for refractory storage symptoms only after confirming PVR <250 mL.

α1-adrenergic antagonists (first-line for symptomatic BPH):

5α-reductase inhibitors (5-ARIs):

Combination α-blocker + 5-ARI: best for large gland + moderate-to-severe symptoms; superior to either alone for progression

Anticholinergics (oxybutynin, tolterodine, solifenacin): add for persistent storage symptoms IF PVR <250 mL — use cautiously in elderly (delirium, falls)

β3-agonist mirabegron: alternative for storage symptoms; fewer cognitive effects; watch BP

PDE5 inhibitor — tadalafil 5 mg daily: approved for LUTS + ED; useful when both coexist

Phytotherapy (saw palmetto): not superior to placebo (CAMUS trial); do not recommend

Surgical and Procedural Management

— Prostatic urethral lift (UroLift): transurethral implants retract obstructing tissue; gland <80 g, no median lobe; preserves ejaculation and erection; office procedure

— Water vapor therapy (Rezūm): convective steam ablates transition zone; 30–80 g; preserves sexual function; results at 3 months

— Temporary implanted nitinol device (iTind): newer option, preserves sexual function

— TURP (transurethral resection of prostate): historical gold standard for 30–80 g; effective, durable; risks: bleeding, TUR syndrome (hyponatremia from hypotonic glycine irrigation — now rare with bipolar/saline), retrograde ejaculation (~65%), urethral stricture, incontinence

— TUIP (transurethral incision of prostate): small glands (<30 g), preserves antegrade ejaculation better

— Bipolar TURP: uses saline irrigation, eliminates TUR syndrome

— HoLEP (holmium laser enucleation): size-independent, excellent for very large glands (>80 g), low transfusion rates, durable; steep learning curve

— GreenLight photoselective vaporization (PVP): good for anticoagulated patients (low bleeding)

— ThuLEP (thulium) — similar to HoLEP

— Hold anticoagulation per procedure (HoLEP/PVP often safer in anticoagulated patients)

— Continuous bladder irrigation post-TURP, foley 1–3 days

— Monitor sodium post-TURP with monopolar glycine setup → watch for confusion, seizures (TUR syndrome)

— Pre-op urine culture; treat UTI before surgery to avoid urosepsis

CCS pearl: Post-TURP patient who becomes confused with nausea and a serum Na of 118 → diagnose TUR syndrome, stop irrigation, give hypertonic saline (3% NaCl) cautiously, and consult urology. Bipolar TURP and laser techniques have largely eliminated this complication.

Indications recap: failed/intolerant medical therapy, recurrent AUR, recurrent UTI, bladder stones, hematuria from BPH, renal insufficiency from obstruction, patient preference.

Minimally invasive office-based procedures (small-to-moderate glands, preserve ejaculation):

Standard transurethral surgeries:

Laser-based:

Simple prostatectomy (open, laparoscopic, or robotic): glands >80–100 g when HoLEP unavailable; higher morbidity but definitive

Prostatic artery embolization (PAE): interventional radiology option for poor surgical candidates; less durable

Periprocedural considerations (CCS-relevant):

Special Populations — Elderly and Renal/Hepatic Impairment

— Polypharmacy and falls are the central concern

— α-blockers → orthostatic hypotension, syncope, hip fracture risk (especially in the first 8 weeks of therapy)

— Dose at bedtime, start low (alfuzosin or tamsulosin preferred — minimal BP drop)

— Avoid doxazosin/terazosin in frail elderly unless treating HTN concurrently

— Anticholinergics on the Beers Criteria — avoid oxybutynin IR in patients >65; if needed, use extended-release or mirabegron

— Cognitive screening before adding antimuscarinics — risk of delirium, dementia acceleration (anticholinergic burden)

— Goals of care discussion: a frail 85-year-old with mild LUTS may be best served by behavioral changes alone

— Tamsulosin, alfuzosin, silodosin: silodosin contraindicated if CrCl <30; reduce dose at CrCl 30–50

— Finasteride/dutasteride: no renal dose adjustment

— Mirabegron: avoid if eGFR <15 or on dialysis; reduce dose if eGFR 15–29

— Trimethoprim-sulfamethoxazole for UTI: watch hyperkalemia and creatinine bump

— BPH causing CKD: post-renal obstruction — decompress with foley, monitor for post-obstructive diuresis (replace ~50–75% of urine output with isotonic fluid; watch electrolytes, hypovolemia)

— Alfuzosin: contraindicated in moderate-to-severe hepatic impairment

— Silodosin: avoid if Child-Pugh C

— Tadalafil: max 5 mg/day, avoid in severe hepatic impairment

— Dutasteride: use with caution

— Avoid combining α-blocker + PDE5 inhibitor without dose separation (≥4 hours) — additive hypotension

— Recent MI, unstable angina, or nitrates: PDE5 inhibitors contraindicated

Board pearl: Catheter decompression of chronic high-volume retention (>1.5 L) commonly triggers post-obstructive diuresis. Admit if output >200 mL/hr for several hours, monitor electrolytes Q6h, and replace with half-normal saline at ~75% of urine output — over-resuscitation perpetuates the diuresis.

Elderly men (>75):

Renal impairment:

Hepatic impairment:

Cardiac comorbidity:

Special Populations — Younger Men, Comorbid Disease, and Other Subgroups

— BPH is uncommon — broaden differential:

— Bladder neck dysfunction / dyssynergia

— Urethral stricture (prior STI, instrumentation, trauma)

— Chronic pelvic pain syndrome / chronic prostatitis (NIH category III)

— Stone disease, bladder/prostate cancer

— Refer to urology earlier; uroflowmetry and cystoscopy frequently needed

— Avoid 5-ARIs if fertility is a concern (decreased semen volume, possible reduced sperm parameters)

— Avoid silodosin and tamsulosin (highest rates of anejaculation)

— Prefer alfuzosin or PDE5i monotherapy

— Surgical: choose UroLift, Rezūm, or iTind to preserve antegrade ejaculation

— Daily tadalafil 5 mg treats both LUTS and ED — one drug, dual benefit

— Counsel on PDE5i + α-blocker timing (separate by ≥4 h) and contraindication with nitrates

— Add antimuscarinic or mirabegron after α-blocker if PVR <250 mL

— Behavioral therapy and bladder training first

— LUTS may be neurogenic, not BPH — UDS essential before surgery (risk of worsened incontinence)

— Consider intermittent self-catheterization, sacral neuromodulation

— Different LUTS profile (incontinence > obstruction); BPH meds rarely apply

— Discuss nocturia's impact (work shifts, religious practices involving fluid intake)

— Cost of dutasteride and tadalafil — generic finasteride and tamsulosin are inexpensive alternatives

Key distinction: A 30-year-old with a weak stream and straining is not BPH — think urethral stricture (history of urethritis, catheter, straddle injury) or primary bladder neck dysfunction. Send for retrograde urethrogram or cystoscopy, not tamsulosin.

Younger men (<50) with LUTS:

Sexually active men prioritizing ejaculatory function:

Men with concurrent ED:

Men with overactive bladder–predominant symptoms:

Neurogenic bladder (MS, Parkinson, stroke, diabetic cystopathy, spinal cord injury):

Post-prostatectomy for cancer:

Cultural and access considerations:

Complications and Adverse Outcomes

— Sudden painful inability to void; suprapubic distention

— Triggers: anticholinergics, sympathomimetics, opioids, alcohol binge, immobilization, UTI, postoperative state, constipation

— Management: immediate Foley catheter (or coudé tip if BPH); leave in for 3–7 days

— Start α-blocker (tamsulosin 0.4 mg) at time of catheter placement — increases successful trial without catheter (TWOC) to ~50–60%

— If TWOC fails twice → urology, likely surgical candidate

— High PVR (often >300 mL), painless, may present with overflow incontinence or silent obstructive uropathy

— Risk of bilateral hydronephrosis, post-renal AKI / CKD

— Stagnant urine in retained bladder; treat infection and address obstruction

— Long-standing BOO → detrusor hypertrophy → eventually detrusor failure (atonic bladder)

— Surgery may not restore function if detrusor failure is established — argues for not delaying intervention indefinitely

— α-blocker orthostasis, syncope, falls, fractures

— 5-ARI sexual dysfunction, gynecomastia, depression; PSA suppression masking cancer

— TUR syndrome (monopolar), retrograde ejaculation, urethral stricture, urinary incontinence, ED post-surgery

CCS pearl: A nursing home resident with new agitation, suprapubic dullness, and decreased urine output → bladder scan at bedside; place a Foley, send UA/culture, review meds for new anticholinergics or opioids. Don't reflex to "delirium workup" without checking the bladder.

Acute urinary retention (AUR):

Chronic urinary retention:

Recurrent UTIs and urosepsis:

Bladder stones and diverticula: chronic incomplete emptying

Hematuria: BPH is a diagnosis of exclusion for hematuria — always rule out malignancy first

Bladder decompensation:

Post-obstructive diuresis (see chunk 9)

Iatrogenic complications:

Psychosocial: sleep deprivation from nocturia → depression, fatigue, work impairment

When to Escalate Care — Referral and Inpatient Triage

— Acute urinary retention with inability to catheterize — call urology for suprapubic cystostomy or coudé/filiform attempts

— Obstructive AKI with hyperkalemia or uremia — admit, decompress, monitor electrolytes

— Urosepsis — IV antibiotics (piperacillin-tazobactam or ceftriaxone + coverage for resistant organisms based on local antibiogram), fluids, urology consult, source control with catheter

— Gross hematuria with clot retention — three-way Foley with continuous bladder irrigation, urology consult

— Suspected prostatic abscess (febrile, fluctuant on DRE, immunocompromised) — imaging + drainage

— Failure of optimized medical therapy after 3–6 months

— Recurrent AUR (≥2 episodes)

— Bladder stones, diverticula, recurrent UTI from retention

— Hematuria (after initial workup) or abnormal DRE/PSA

— Suspected neurogenic bladder, prior pelvic surgery/radiation

— Patient considering surgical intervention

— Nephrology for CKD progression

— Cardiology before surgery in high-risk patients (RCRI assessment)

— Anesthesia/preoperative clinic for frailty assessment

— At ED discharge after AUR: ensure follow-up within 3–7 days for TWOC and urology referral

— Document catheter type, size, date placed; instruct on leg-bag use and signs of obstruction/infection

— Medication reconciliation — stop offending agents

— Communicate diagnosis and plan to PCP via discharge summary

— Orders: Foley with output monitoring, BMP Q6–12h, UA/culture, renal US if obstruction suspected, IV fluids cautious for post-obstructive diuresis, urology consult, start tamsulosin

Step 3 management: Send any patient discharged after AUR home with a leg-bag catheter, an α-blocker, and a scheduled urology visit within 1 week for TWOC. Skipping the α-blocker before catheter removal halves the success rate.

Urgent ED/inpatient triage:

Outpatient urology referral (non-urgent but indicated):

Specialty co-management:

Care transitions (Step 3 emphasis):

CCS framing of inpatient BPH admission:

Key Differentials — Other Causes of LUTS (Same Category)

— Storage symptoms dominate: urgency, frequency, urge incontinence

— Often without obstructive symptoms; normal uroflow

— Treat with behavioral therapy, antimuscarinics, mirabegron, sacral neuromodulation, intravesical botulinum toxin

— Younger men; history of STI, instrumentation, trauma, hypospadias repair

— Weak stream out of proportion to age and prostate size

— Diagnose with retrograde urethrogram or cystoscopy

— Treat with dilation, urethrotomy, or urethroplasty — α-blockers won't help

— Young men, often with normal prostate

— UDS shows obstruction at bladder neck

— Treat with α-blocker or TUIP

— Usually asymptomatic until advanced; can cause LUTS when bulky

— Hard nodular prostate, elevated PSA, weight loss, bone pain

— Workup: MRI, biopsy

— Acute: fever, perineal pain, tender boggy prostate, pyuria — treat with fluoroquinolone or TMP-SMX 4–6 weeks

— Chronic bacterial: recurrent UTI with same organism, prolonged ciprofloxacin

— Chronic pelvic pain syndrome (NIH IIIa/b): pain >3 months, often refractory; multimodal therapy

— Painless gross or microscopic hematuria, irritative symptoms, smoking history

— Cystoscopy + CT urogram + urine cytology

— Intermittent stream, hematuria, dysuria, suprapubic pain

— MS, Parkinson, stroke, spinal cord injury, diabetic cystopathy

— UDS to characterize; may need ISC, anticholinergics, or neuromodulation

Key distinction: Urgency-predominant LUTS with normal flow and small prostate = overactive bladder, not BPH. Starting tamsulosin won't help and may cause orthostasis. Treat with bladder training + antimuscarinic/mirabegron instead.

Overactive bladder (OAB) / detrusor overactivity:

Urethral stricture:

Bladder neck dysfunction / primary bladder neck obstruction:

Prostate cancer:

Acute or chronic prostatitis:

Bladder cancer:

Bladder stones / foreign body:

Neurogenic bladder:

Key Differentials — Other-Category Mimics

— Uncontrolled diabetes mellitus — osmotic diuresis; check glucose/A1c, urinalysis for glucosuria

— Diabetes insipidus — large-volume dilute urine, polydipsia; water deprivation test

— Hypercalcemia — nephrogenic DI picture

— Diuretic use — especially evening dosing causing nocturia (switch to morning dosing)

— Excess fluid/caffeine/alcohol intake

— Heart failure (third spacing redistributes at night when supine)

— Obstructive sleep apnea (suppressed ANP release, treat with CPAP)

— Peripheral edema from venous insufficiency, CCBs

— Late-evening fluid intake

— Age-related loss of nocturnal ADH surge — desmopressin nasal spray (cautiously in elderly: hyponatremia risk)

— Diuretics → frequency/nocturia

— α-blockers used for HTN may incidentally improve LUTS

— Normal pressure hydrocephalus — gait/cognition/urinary triad

— Cauda equina — saddle anesthesia, bilateral leg weakness, retention → emergent MRI

— MS, Parkinson, stroke — neurogenic bladder

— Pelvic mass, rectal tumor, fecal impaction

— Inguinal hernia containing bladder

— Anxiety-driven frequency without nocturia

— Functional incontinence in mobility-limited patients

Board pearl: A 70-year-old with nocturia, leg swelling, and dyspnea on exertion has heart failure–driven nocturnal polyuria, not BPH. Optimize diuretics (morning dose), compression stockings, and consider CPAP if OSA — and you'll fix the "BPH."

Polyuria from systemic disease (presents as "frequency"):

Nocturnal polyuria (>33% of 24-h output at night):

Cardiovascular medications causing urinary symptoms:

Neurologic disease mimicking BPH:

Pelvic pathology compressing bladder/urethra:

Psychogenic / functional:

Secondary Prevention and Long-Term Plan

— Weight loss in obese patients — reduces LUTS progression

— Regular aerobic exercise (≥150 min/week) — independently associated with reduced BPH progression

— Mediterranean-style diet, reduced red meat

— Glycemic control (A1c targets per ADA)

— Blood pressure and lipid management

— Limit caffeine, alcohol, especially in the evening

— Smoking cessation (cardiovascular benefit, bladder cancer reduction)

— α-blocker monotherapy: continue indefinitely if effective and tolerated; reassess annually

— 5-ARI: counsel that benefit takes 3–6 months; monitor PSA at 6 months to establish new baseline (any subsequent rise from this new nadir is concerning for cancer even if absolute value is "normal")

— Combination therapy: continue both; some patients can discontinue α-blocker after 6–12 months of 5-ARI shrinkage

— Periodic medication reconciliation to remove new anticholinergics/sympathomimetics

— TURP/HoLEP: durable benefit 10–15 years; ~5–10% need re-treatment over a decade

— UroLift/Rezūm: less durable, ~10–15% retreatment at 5 years

— Resume α-blocker only if symptoms recur; many patients can stop all BPH meds post-surgery

— Continue shared decision-making PSA screening per USPSTF (ages 55–69, individualized) — adjusting interpretation for 5-ARI use

— Continue colorectal cancer screening (often forgotten in men focused on urologic care)

— Influenza annually, pneumococcal per age/risk, shingles, COVID boosters

— Bone health if on long-term steroids or low testosterone

Step 3 management: After starting a 5-ARI, recheck PSA at 6 months and record this as the new baseline. From then on, treat any confirmed PSA rise above this nadir as a red flag for prostate cancer — don't be reassured by an "in-range" number.

Modifiable risk factor management:

Long-term medication management:

Post-surgical long-term plan:

Cancer screening integration:

Vaccinations and preventive care:

Address sexual health: discuss ED, ejaculatory changes openly; offer PDE5i, counseling, refer to sexual medicine if needed

Follow-Up, Monitoring Parameters, and Counseling

— After initiating medical therapy: reassess at 4–6 weeks for α-blocker effect and tolerability

— After starting 5-ARI: 3–6 months to assess symptom response; recheck PSA at 6 months

— Stable on therapy: annual visit with IPSS, DRE, focused history; PSA per shared decision-making

— After AUR with TWOC: urology visit within 1 week; PCP follow-up at 2–4 weeks

— Post-surgical: urology at 4–6 weeks, then 3–6 months; PCP for medication reconciliation

— IPSS/AUA-SI score trend

— Bother/QoL score

— Adverse effects: orthostasis (check orthostatic vitals in elderly), sexual function, mood

— DRE annually

— PSA per protocol

— Basic metabolic panel if on diuretics, ACEi/ARB, or CKD

— Voiding diary if nocturia worsens

— Bladder scan PVR if symptoms progress or new retention

— Set expectations: α-blockers work in days; 5-ARIs take months

— Avoid driving until orthostatic effects of α-blocker known (first dose at bedtime)

— Inform ophthalmologist of tamsulosin use before cataract surgery (IFIS)

— 5-ARI: do not let pregnant partners handle crushed tablets; semen exposure precautions (no clear evidence of fetal harm at usual exposure but counsel)

— Recognize AUR symptoms; have a plan for after-hours catheterization

— Pelvic floor exercises, double voiding, scheduled voiding

— Send IPSS scores in chart for trending

— Communicate with anesthesia/ophthalmology/cardiology preoperatively

— Engage caregivers in nursing home or home health settings

CCS pearl: On the CCS interface, after starting tamsulosin advance the clock 4–6 weeks, reassess IPSS and orthostatic vitals, and titrate or add a 5-ARI based on prostate size and PSA — short interval visits demonstrate appropriate longitudinal management.

Follow-up cadence:

Monitoring parameters at each visit:

Patient counseling points:

Coordination of care:

Ethical, Legal, and Patient Safety Considerations

— Retrograde ejaculation: ~65% after TURP, ~10–20% after Rezūm, <5% after UroLift — must be discussed, especially in men of reproductive age or those for whom orgasmic sensation matters

— Erectile dysfunction (~5–10% new ED post-TURP)

— Urinary incontinence (~1–2%)

— Need for re-treatment, urethral stricture, bleeding, infection

— Document patient understanding in the chart — failure to disclose ejaculatory effects is a common malpractice issue

— USPSTF: ages 55–69, individualize; ≥70, against routine screening

— Document discussion of overdiagnosis, overtreatment, and benefits

— 5-ARI distorts PSA — clearly note this in the chart and communicate to any covering clinician

— Avoid anticholinergics and α1-blockers (especially nonselective) in frail elderly when possible

— Document fall-risk counseling when starting α-blockers

— Tamsulosin + IFIS: notify cataract surgeon (transition-of-care safety issue)

— CAUTI is a "never event" in many payer systems

— Use indwelling catheters only when necessary; remove ASAP; consider intermittent catheterization

— Document indication daily on inpatient list

— Clear handoff to urology with catheter date, plan for TWOC, and α-blocker prescription — dropped follow-up leads to chronic retention, hydronephrosis, sepsis

— Older patients with cognitive impairment may need surrogate decision-makers for surgical consent — assess capacity formally

— Access to urology and advanced procedures varies; offer telehealth follow-up; ensure interpreter services for non-English speakers during informed consent

Board pearl: A man considering TURP who is planning future biological children must be counseled that retrograde ejaculation is highly likely and to consider sperm banking beforehand. Documenting this conversation is both an ethical and medicolegal imperative.

Informed consent for BPH surgery — explicit risk disclosure:

Shared decision-making in PSA screening:

Patient safety — Beers Criteria and polypharmacy:

Catheter-related safety:

Transitions of care after AUR:

Decision-making capacity:

Health equity:

High-Yield Associations and Rapid-Fire Clinical Facts

— BPH adds ~0.3 ng/mL per gram of tissue

— Acute prostatitis can spike PSA to >50

— 5-ARIs halve PSA after 6 months → double the value to interpret

— Vigorous exercise, recent ejaculation (48 h), catheterization, prostate biopsy all raise PSA

— Tamsulosin → IFIS during cataract surgery

— Silodosin → highest rate of retrograde ejaculation; avoid if CrCl <30

— Finasteride → reduces PSA by ~50%, may cause gynecomastia, sexual dysfunction; pregnancy category X

— Dutasteride dual inhibitor of 5-AR types 1 and 2

— Tadalafil 5 mg daily treats LUTS + ED; avoid with nitrates

— Mirabegron β3-agonist, watch BP

— MTOPS: combo (doxazosin + finasteride) > monotherapy for progression

— CombAT: dutasteride + tamsulosin > monotherapy for AUR/surgery reduction

— CAMUS: saw palmetto = placebo

— REDUCE / PCPT: 5-ARIs reduce overall prostate cancer but slightly increase high-grade detection (interpretation debated)

— TUR syndrome (hypoosmolar hyponatremia) — monopolar glycine resection

— HoLEP — size-independent, low bleeding

— UroLift/Rezūm — preserve ejaculation

— Simple prostatectomy — glands >80 g

Key distinction: Transition zone = BPH; peripheral zone = cancer. A normal DRE does NOT rule out BPH (transition zone not palpable). A hard nodule on DRE does NOT mean BPH is absent — they often coexist.

Anatomy: BPH arises in the transition zone; prostate cancer typically in the peripheral zone — this is why DRE catches cancer but misses BPH bulk.

PSA dynamics:

Drug pearls:

Trial mnemonics:

Surgical pearls:

AUR triggers: anticholinergics, sympathomimetics, opioids, alcohol, immobilization, constipation, postoperative state

Post-obstructive diuresis: replace ~75% urine output with half-normal saline, monitor electrolytes Q6h

Pearl on screening: continue colorectal, lipid, BP, diabetes screening — don't lose preventive care in urology-heavy visits.

Board Question Stem Patterns

— 62-year-old man, IPSS 16, normal DRE, PSA 1.0, prostate ~25 g on TRUS, normal PVR. Best initial pharmacotherapy?

— Answer: tamsulosin (small gland, no progression risk features → α-blocker monotherapy)

— 70-year-old, IPSS 22, PSA 3.5, prostate 70 g, prior AUR episode. Best therapy?

— Answer: combination tamsulosin + dutasteride/finasteride (large gland, high progression risk)

— Man on tamsulosin scheduled for cataract surgery. Next step?

— Answer: inform ophthalmologist; do not stop tamsulosin assuming it will reverse risk

— Man on finasteride 1 year, PSA rose from nadir 1.5 to 3.0. Next step?

— Answer: urology referral / biopsy consideration — doubling from nadir on 5-ARI is concerning

— 75-year-old presents with painful inability to void, suprapubic distention. Next step?

— Answer: catheterize immediately, start α-blocker, plan TWOC in 3–7 days

— Confused, hyponatremic, nauseated patient mid-TURP. Diagnose and treat.

— Answer: stop irrigation, hypertonic saline, supportive care

— 68-year-old smoker with LUTS and microscopic hematuria. Next step?

— Answer: cystoscopy + CT urogram, not "start tamsulosin"

— Older man with isolated nocturia, leg edema, OSA history. Best management?

— Answer: treat CHF/OSA, morning diuretic dosing, compression stockings — not α-blocker

— Elderly man with high PVR and storage symptoms. Adding oxybutynin causes confusion and worse retention.

— Lesson: check PVR before antimuscarinics; consider mirabegron or behavioral therapy

— Man with both conditions, not on nitrates.

— Answer: daily tadalafil 5 mg

Step 3 management: Match the answer to gland size, PSA, progression risk, sexual priorities, and comorbidities — these five variables drive every BPH question.

Stem 1 — "Start the α-blocker":

Stem 2 — "Add the 5-ARI":

Stem 3 — "Watch for IFIS":

Stem 4 — "PSA on 5-ARI":

Stem 5 — "Acute retention triage":

Stem 6 — "TUR syndrome":

Stem 7 — "Don't miss bladder cancer":

Stem 8 — "Nocturnal polyuria":

Stem 9 — "Avoid anticholinergic in elderly":

Stem 10 — "Tadalafil for LUTS + ED":

One-Line Recap

BPH is a clinical syndrome of LUTS in aging men managed by a stepwise outpatient algorithm — lifestyle and medication review, α-blocker for symptom relief, add a 5-ARI when prostate is large (>30–40 g) or PSA >1.5, combine with tadalafil or antimuscarinic/mirabegron for overlapping ED or storage symptoms, and refer for TURP/HoLEP/UroLift/Rezūm when medical therapy fails or complications (recurrent AUR, UTI, stones, hematuria, renal injury) develop — while never letting the BPH label obscure red flags for prostate cancer, bladder cancer, urethral stricture, neurogenic bladder, or systemic polyuria.

Board pearl: The five variables that decide every BPH management question are prostate size, PSA, progression risk, sexual priorities, and comorbidities — anchor your answer to those and you'll get the Step 3 stem right every time.

Diagnose: IPSS + bother score, UA, PSA (shared decision), DRE, PVR; cystoscopy/CT urogram for hematuria.

Treat by progression risk: small gland → α-blocker; large gland/high PSA → α-blocker + 5-ARI; coexisting ED → daily tadalafil 5 mg; storage symptoms with PVR <250 → antimuscarinic or mirabegron.

Operate when: refractory symptoms, recurrent AUR/UTI, bladder stones, hydronephrosis, gross hematuria; choose procedure by gland size (UroLift/Rezūm <80 g preserve ejaculation; TURP 30–80 g; HoLEP/simple prostatectomy >80 g).

Safety nets: double PSA on 5-ARI, notify ophthalmology of tamsulosin before cataract surgery, post-obstructive diuresis monitoring after high-volume retention drainage, AUR follow-up within 1 week with α-blocker on board, and always rule out cancer and neurogenic causes before locking in the BPH label.